Copyright @ 2006 by the American Association of Neuropathologists, Inc. Unauthorized reproduction of this article is prohibited. ORIGINAL ARTICLE Biochemical Staging of Synucleinopathy and Amyloid Deposition in Dementia With Lewy Bodies

The primary feature of dementia with Lewy bodies (DLB) is the aggregation of alpha-synuclein into characteristic lesions: Lewy bodies (LBs) and Lewy neurites. However, in most of DLB cases, LBs are associated with neurofibrillary tangles and amyloid plaques (both Alzheimer disease [AD]-related lesions). We wanted to determine if this overlap of lesions is statistical, as a result of the late onset of both diseases, or results from a specific physiopatho-logical synergy between synucleinopathy and either tauopathy or amyloid pathology. All patients with DLB from our prospective and multidisciplinary study were analyzed. These cases were compared with cases with pure AD and patients with Parkinson disease and controls. All cases were analyzed thoroughly at the neuropathologic and biochemical levels with a biochemical staging of aggregated>-synuclein, tau, and AA species. All sporadic cases of DLB were associated with abundant deposits of AA x-42 that were similar in quality and quantity to those of AD. Amyloid precursor protein (APP) dysfunction is a risk factor for AD as demonstrated by pathogenic mutations and AA accumulation. The constant and abundant AA x-42 deposition in sporadic DLB suggests that synucleinopathy is also promoted by APP dysfunc-tion. Therefore, we conclude that APP is a therapeutic target for both AD and DLB